CN105055352A - Trimetazidine hydrochloride tablets and preparation method thereof - Google Patents

Trimetazidine hydrochloride tablets and preparation method thereof Download PDF

Info

Publication number
CN105055352A
CN105055352A CN201510490401.4A CN201510490401A CN105055352A CN 105055352 A CN105055352 A CN 105055352A CN 201510490401 A CN201510490401 A CN 201510490401A CN 105055352 A CN105055352 A CN 105055352A
Authority
CN
China
Prior art keywords
trimetazidine hydrochloride
hydrochloride tablets
tablets
healthy
trimetazidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510490401.4A
Other languages
Chinese (zh)
Inventor
苗得足
黄京山
李伟
刘乐凯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reyoung Pharmaceutical Co Ltd
Original Assignee
Reyoung Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reyoung Pharmaceutical Co Ltd filed Critical Reyoung Pharmaceutical Co Ltd
Priority to CN201510490401.4A priority Critical patent/CN105055352A/en
Publication of CN105055352A publication Critical patent/CN105055352A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention belongs to the technical field of medicine and particularly relates to trimetazidine hydrochloride tablets and a preparation method thereof. The trimetazidine hydrochloride tablets are prepared from raw materials as follows: trimetazidine hydrochloride, filler, a binder, a lubricant and a wetting agent. The trimetazidine hydrochloride tablets solve the problems of poor compressibility and difficulty in forming of the trimetazidine hydrochloride as the raw material. The invention further provides the preparation method of the trimetazidine hydrochloride tablets. The compressibility of the prepared trimetazidine hydrochloride tablets is improved, the trimetazidine hydrochloride tablets are formed easily, the use value of the trimetazidine hydrochloride tablets can be increased better, trimetazidine hydrochloride is prepared into tablets to facilitate taking of a patient, pain of the patient can be relieved timely, the process is simple, the quality is stable, a production process meets the requirement of GMP (Good Manufacture Practice of Drugs), and the trimetazidine hydrochloride tablets and the preparation method are applicable to industrial mass production.

Description

Trimetazidine Hydrochloride Tablets in healthy and preparation method thereof
Technical field
The invention belongs to medical art, be specifically related to a kind of Trimetazidine Hydrochloride Tablets in healthy and preparation method thereof.
Background technology
Trimetazidine Hydrochloride Tablets in healthy is clinical is applicable to arteria coronaria functional defect, angina pectoris, the angina pectoris that hemodynamics drug treatment alone is invalid, diabetic coronary artery disease, old myocardial infarction etc.Trimetazidine Hydrochloride Tablets in healthy belongs to other class antianginal cardiovascular drugses; trimetazidine is by the energy metabolism of Cell protection under anoxia or ischemia; stop the decline of intracellular ATP levels; thus ensure that the normal function of ionic pump and the normal operation of permeable membrane sodium-potassium stream, maintain the stable of intracellular environment.Zooscopy finds: trimetazidine: help to maintain heart and the energy metabolism of neural sensation organ in ischemia and hypoxia situation.The change of the permeable membrane ion flow reducing intracellular acidosis and caused by ischemia.While this effect of generation, hematodinamics is had no significant effect.Its curative effect is reliable, and side effect is little, toleration.The Trimetazidine Hydrochloride Tablets in healthy of auspicious positive pharmaceutical manufacturing enjoys a good market both at home and abroad market, relieves slight illness to countless patient.Also good economic benefit and social benefit is achieved.
Angina pectoris is coronary insufficiency, cardiac muscle sharply, caused by ischemia and anoxia be the clinical syndrome of main manifestations with ictal chest pain or chest discomfort.Update shows, and China's cardiovascular patient prevalence is in lasting ascent stage, reaches 2.3 hundred million before ill total number, on average just has 1 people to suffer from heart disease in every 5 adults.The patient that cardiovascular diseases's disease is died from the whole nation every year has 3,500,000.The paathogenic factor that to be all the cardiovascular risk factors of generally acknowledging at present the be cardiovascular disease such as smoking, diabetes, hypertension, obesity, hyperlipidemia is important, along with the increase of living-pattern preservation and operating pressure, cardiovascular patient prevalence is in lasting ascent stage.
Summary of the invention
Bad for existing Trimetazidine Hydrochloride compressibility, the shortcoming that molding is more difficult, the object of this invention is to provide a kind of Trimetazidine Hydrochloride Tablets in healthy, compressibility strengthens, easy-formation, better can improve the use value of Trimetazidine Hydrochloride Tablets in healthy, the present invention also provides its preparation method, technique is simple, steady quality.
A kind of Trimetazidine Hydrochloride Tablets in healthy, be made up of the raw material of following parts by weight:
Trimetazidine Hydrochloride 2.2-2.4 part, filler 6.0-6.2 part, binding agent 0.4-0.5 part, lubricant 0.3-0.4 part and wetting agent 1.2-1.4 part.
Wherein:
Binding agent is selected from ethyl cellulose, PVP K30, one or more in polyethylene glycol 6000, methylcellulose or hypromellose; Binding agent effectively can play adhesive effect, adds compressibility.
Filler be selected from starch, pregelatinized Starch, lactose, microcrystalline Cellulose, dextrin or mannitol one or more.
Lubricant be selected from Pulvis Talci, magnesium stearate, silicon dioxide or Stepanol MG one or more.
Wetting agent is selected from one or more of arabic gum alcoholic solution or tragakanta alcoholic solution.Wherein: it is 20% arabic gum alcoholic solution that arabic gum alcoholic solution is preferably concentration; Tragakanta alcoholic solution is preferably the tragakanta alcoholic solution that concentration is 20%.
The preparation method of described Trimetazidine Hydrochloride Tablets in healthy, is prepared by following preparation method:
(1) Trimetazidine Hydrochloride is crossed 22 order mesh screens;
(2) Trimetazidine Hydrochloride, filler and binding agent mix homogeneously that step (1) obtains is taken;
(3) add wetting agent, granulate with 18 order mesh screens, dry, granulate;
(4) add lubricant always mixed rear tabletting, obtain Trimetazidine Hydrochloride Tablets in healthy.
The present invention adopts effective ingredient and special solid preparation adjuvant to prepare Trimetazidine Hydrochloride Tablets in healthy, and adopt filler and wetting agent synergism, filler brings out cohesive through wetting agent, adds compressibility; Lubricant adds the mobility of granule simultaneously, indirectly adds compressibility.
The invention solves the problem that the compressibility of Trimetazidine Hydrochloride is poor, make Trimetazidine Hydrochloride make tablet easily, be conducive to playing its therapeutic effect.
The present invention compared with prior art, has following beneficial effect:
(1) the invention solves raw material Trimetazidine Hydrochloride compressibility bad, the shortcoming that molding is more difficult, Trimetazidine Hydrochloride Tablets in healthy compressibility prepared by the present invention strengthens, easy-formation, better can improve the use value of Trimetazidine Hydrochloride Tablets in healthy, making tablet facilitates patient to take, and is conducive to removing patient's slight illness in time.
(2) Trimetazidine Hydrochloride Tablets in healthy preparation method technique of the present invention is simple, steady quality, and production process meets the requirement of GMP, is applicable to industrialized great production.
(3) Trimetazidine Hydrochloride Tablets in healthy that prepared by the present invention is conducive to giving full play to Trimetazidine Hydrochloride Tablets in healthy therapeutical effect, can be used for the prophylactic treatment of angina pectoris attacks, the complementary symptomatic treatment of dizzy and tinnitus, this medicine is the stronger anti-anginal drug of effect, and the persistent period is longer.There is the effect to antiadrenergic drug, norepinephrine and vassopressin, can vascular resistance be reduced, increase coronary flow and surrounding loop blood flow, promote the generation of myocardial metabolism and cardiac energy.Heart working load can be lowered simultaneously.Reduce the consumption of myocardial oxygen consumption and cardiac energy, thus improve the equilibrium of supply and demand of myocardium oxygen.Still can increase the toleration to cardiotonic glycoside.
Detailed description of the invention
Below in conjunction with embodiment, the present invention will be further described.
Embodiment 1
1, prescription
2, technique
Trimetazidine Hydrochloride is crossed 22 order mesh screens.2.2kg Trimetazidine Hydrochloride, 2.8kg microcrystalline Cellulose, 3.4kg pregelatinized Starch and 0.4kg polyethylene glycol 6000 mix homogeneously is taken by prescription.Add the tragakanta alcoholic solution that 1.3kg concentration is 20%, granulate with 18 order mesh screens, dry, granulate.Add 0.3kg Stepanol MG and 0.1kg magnesium stearate always mixed after tabletting namely obtain Trimetazidine Hydrochloride Tablets in healthy of the present invention.
Embodiment 2
1, prescription
2, technique
Trimetazidine Hydrochloride is crossed 22 order mesh screens.2.4kg Trimetazidine Hydrochloride, 2.7kg mannitol, 3.3kg lactose and 0.5kg methylcellulose mix homogeneously is taken by prescription.Add the arabic gum alcoholic solution that 1.4kg concentration is 20%, granulate with 18 order mesh screens, dry, granulate.Add 0.15kg silicon dioxide and 0.15kg Pulvis Talci always mixed after tabletting namely obtain Trimetazidine Hydrochloride Tablets in healthy of the present invention.
Embodiment 3
1, prescription
2, technique
Trimetazidine Hydrochloride is crossed 22 order mesh screens.2.3kg Trimetazidine Hydrochloride, 2.9kg dextrin, 3.2kg lactose and 0.4kg hypromellose mix homogeneously is taken by prescription.Add the arabic gum alcoholic solution that 1.2kg concentration is 20%, granulate with 18 order mesh screens, dry, granulate.Add 0.1kg Stepanol MG and 0.2kg Pulvis Talci always mixed after tabletting namely obtain Trimetazidine Hydrochloride Tablets in healthy of the present invention.
Embodiment 4
1, prescription
2, technique
Trimetazidine Hydrochloride is crossed 22 order mesh screens.2.2kg Trimetazidine Hydrochloride, 2.4kg starch, 3.6kg dextrin and 0.5kg ethyl cellulose mix homogeneously is taken by prescription.Add the tragakanta alcoholic solution that 1.3kg concentration is 20%, granulate with 18 order mesh screens, dry, granulate.Add 0.2kg Stepanol MG and 0.1kg silicon dioxide always mixed after tabletting namely obtain Trimetazidine Hydrochloride Tablets in healthy of the present invention.
Embodiment 5
1, prescription
2, technique
Trimetazidine Hydrochloride is crossed 22 order mesh screens.2.4kg Trimetazidine Hydrochloride, 6.1kg microcrystalline Cellulose and 0.4kg PVP K30 mix homogeneously is taken by prescription.Add the arabic gum alcoholic solution that 1.4kg concentration is 20%, granulate with 18 order mesh screens, dry, granulate.Add 0.3kg magnesium stearate always mixed after tabletting namely obtain Trimetazidine Hydrochloride Tablets in healthy of the present invention.
According to the relevant regulations of national Bureau of Drugs Supervision standard YBH13562005 and CP2010, detect the product that embodiment 1-5 prepares, concrete outcome is in table 1.
The testing result of the product that table 1 embodiment 1-5 prepares
Sample source Dissolution Weight differential Hardness Friability Disintegration
Embodiment 1 98% 2.3% 112.7N 0.49% 6.5min
Embodiment 2 99% 3.5% 124.1N 0.43% 5.7min
Embodiment 3 97% 4.1% 131.4N 0.34% 6.2min
Embodiment 4 101% 3.3% 119.3N 0.38% 5.2min
Embodiment 5 100% 3.2% 109.9N 0.51% 6.0min

Claims (8)

1. a Trimetazidine Hydrochloride Tablets in healthy, is characterized in that: be made up of the raw material of following parts by weight:
Trimetazidine Hydrochloride 2.2-2.4 part, filler 6.0-6.2 part, binding agent 0.4-0.5 part, lubricant 0.3-0.4 part and wetting agent 1.2-1.4 part.
2. Trimetazidine Hydrochloride Tablets in healthy according to claim 1, is characterized in that: binding agent is selected from ethyl cellulose, PVP K30, one or more in polyethylene glycol 6000, methylcellulose or hypromellose.
3. Trimetazidine Hydrochloride Tablets in healthy according to claim 1, is characterized in that: filler be selected from starch, pregelatinized Starch, lactose, microcrystalline Cellulose, dextrin or mannitol one or more.
4. Trimetazidine Hydrochloride Tablets in healthy according to claim 1, is characterized in that: lubricant be selected from Pulvis Talci, magnesium stearate, silicon dioxide or Stepanol MG one or more.
5. Trimetazidine Hydrochloride Tablets in healthy according to claim 1, is characterized in that: wetting agent is selected from one or more of arabic gum alcoholic solution or tragakanta alcoholic solution.
6. Trimetazidine Hydrochloride Tablets in healthy according to claim 5, is characterized in that: arabic gum alcoholic solution is concentration is 20% arabic gum alcoholic solution.
7. Trimetazidine Hydrochloride Tablets in healthy according to claim 5, is characterized in that: tragakanta alcoholic solution to be concentration be 20% tragakanta alcoholic solution.
8. a preparation method for the arbitrary described Trimetazidine Hydrochloride Tablets in healthy of claim 1-7, is characterized in that: be prepared by following preparation method:
(1) Trimetazidine Hydrochloride is crossed 22 order mesh screens;
(2) Trimetazidine Hydrochloride, filler and binding agent mix homogeneously that step (1) obtains is taken;
(3) add wetting agent, granulate with 18 order mesh screens, dry, granulate;
(4) add lubricant always mixed rear tabletting, obtain Trimetazidine Hydrochloride Tablets in healthy.
CN201510490401.4A 2015-08-11 2015-08-11 Trimetazidine hydrochloride tablets and preparation method thereof Pending CN105055352A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510490401.4A CN105055352A (en) 2015-08-11 2015-08-11 Trimetazidine hydrochloride tablets and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510490401.4A CN105055352A (en) 2015-08-11 2015-08-11 Trimetazidine hydrochloride tablets and preparation method thereof

Publications (1)

Publication Number Publication Date
CN105055352A true CN105055352A (en) 2015-11-18

Family

ID=54485038

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510490401.4A Pending CN105055352A (en) 2015-08-11 2015-08-11 Trimetazidine hydrochloride tablets and preparation method thereof

Country Status (1)

Country Link
CN (1) CN105055352A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105434380A (en) * 2015-12-11 2016-03-30 南京正科医药股份有限公司 Trimetazidine dihydrochloride tablet
CN111557922A (en) * 2020-06-28 2020-08-21 江苏吴中医药集团有限公司 Trimetazidine hydrochloride preparation and preparation method thereof
CN107982231B (en) * 2018-01-03 2021-05-07 江苏吴中医药集团有限公司 Trimetazidine hydrochloride tablet and preparation method thereof
CN117797152A (en) * 2023-12-29 2024-04-02 海南锦麟医药科技有限公司 Medicine for protecting cell nourishing myocardial cells and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407801A (en) * 1980-09-30 1983-10-04 Science Union Et Cie Anti-ischemic pharmaceutic compositions
CN101283992A (en) * 2008-05-29 2008-10-15 胡传良 Trimetazidine hydrochloride dispersible tablet and preparation method thereof
CN103239417A (en) * 2012-02-13 2013-08-14 瑞阳制药有限公司 Preparation method of trimetazidine dihydrochloride tablet

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407801A (en) * 1980-09-30 1983-10-04 Science Union Et Cie Anti-ischemic pharmaceutic compositions
CN101283992A (en) * 2008-05-29 2008-10-15 胡传良 Trimetazidine hydrochloride dispersible tablet and preparation method thereof
CN103239417A (en) * 2012-02-13 2013-08-14 瑞阳制药有限公司 Preparation method of trimetazidine dihydrochloride tablet

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
罗明生 等主编: "《药剂辅料大全》", 31 March 1993, 四川科学技术出版社 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105434380A (en) * 2015-12-11 2016-03-30 南京正科医药股份有限公司 Trimetazidine dihydrochloride tablet
CN107982231B (en) * 2018-01-03 2021-05-07 江苏吴中医药集团有限公司 Trimetazidine hydrochloride tablet and preparation method thereof
CN111557922A (en) * 2020-06-28 2020-08-21 江苏吴中医药集团有限公司 Trimetazidine hydrochloride preparation and preparation method thereof
CN117797152A (en) * 2023-12-29 2024-04-02 海南锦麟医药科技有限公司 Medicine for protecting cell nourishing myocardial cells and preparation method thereof

Similar Documents

Publication Publication Date Title
CN105055352A (en) Trimetazidine hydrochloride tablets and preparation method thereof
JP2013532666A (en) Anti-fatigue composition, its formulation and application
MX2015004296A (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof.
CN101283992A (en) Trimetazidine hydrochloride dispersible tablet and preparation method thereof
JP2019131597A (en) Super quick decomposition tablet and production method thereof
JP6479658B2 (en) Super-fast disintegrating tablet and method for producing the same
CN111991362A (en) Ticagrelor sustained release tablet and preparation method thereof
CN106214653A (en) A kind of FCE-26743A slow releasing tablet and preparation method thereof
CN103860511B (en) A kind of Pharmaceutical composition containing Irbesartan and Amlodipine Besylate Tablet and preparation method thereof
JP6469234B2 (en) Super-fast disintegrating tablet and method for producing the same
CN112618504B (en) Medicinal composition containing erigeron breviscapus extract and borneol and preparation method thereof
CN103599140A (en) Bilobalide controlled release tablet and preparation method thereof
CN103919790B (en) A kind of preparation method of sulfaguanidine-trimethoprim effervescent tablet
CN103656609A (en) Trandolapril dispersion pharmaceutical composition
JP5982715B2 (en) Antihypertensive composition
CN105193758A (en) Gliclazide sustained release tablets and preparation method thereof
WO2022036506A1 (en) Composition and use of sglt-2 inhibitor and angiotensin receptor blockers
CN115671070B (en) Desloratadine citrate osmotic pump controlled release tablet and preparation method thereof
CN115154448B (en) Medicine for treating restless leg syndrome and preparation method and application thereof
CN107582866A (en) Dendrobium candidum and Amlodipine are preparing the application process in treating hypertension drug
CN101467985B (en) Bisoprolol fumarate dispersible tablet and preparation method thereof
CN105796514A (en) Alogliptin benzoate oral disintegrating tablet and preparation method thereof
CN106176761A (en) A kind of new application of the compositions comprising isosorbide mononitrate and Ivabradine
EP2374457B1 (en) Antihypertensive pharmaceutical composition
CN105287550A (en) Valsartan/felodipine compound preparation and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20151118